Info
TKI discontinuation
consider if complete molecular response (>4.5 log reduction in BCR-ABL1 transcript) for >2 y. Up to 50% of Pts remain off TKI at 2 y (ie, no molec. recurrence). Success proportional to duration of CMR and risk score at presentation.